卢秉久教授辨证治疗慢性乙型肝炎经验被引量：5

Professor LU Bing-jiu's Experience on Treatment of Chronic Hepatitis Syndrome

下载PDF

导出

摘要卢秉久教授对慢乙肝的治疗有独到之处,逐渐形成了自己独特的学术思路,愈者甚多。从病因病机、辨证论治(分五型:肝胆湿热型用龙胆泻胆丸加减,肝郁脾虚型用逍遥散加减,肝胃不和型常用平胃散加减,肝肾阴虚型用一贯煎加减,肝脾血瘀型用复原活血汤加减)方面介绍了卢秉久教授辨证治疗慢性乙型肝炎的经验。 Professor LU Bing-jiu on the treatment of chronic hepatitis B with one＇s own knack in,gradually formed its own unique academic ideas,more and more many.From the etiology and pathogenesis,syndrome differentiation and treatment（divided into five types： type of damp heat in liver and gall with gentian and bile pill ＂,liver stagnation and spleen deficiency type with Modified Xiaoyao decoction,liver stomach disharmony type commonly used Pingwei Powder addition and subtraction,liver and kidney yin deficiency type with consistent decoction,blood stasis type with the restoration and Activating Blood Decoction） introduces professor Lu Bingjiu syndrome differentiation and treatment of chronic hepatitis B.

作者鞠咏纳于成文张洋卢秉久

机构地区岫岩县中心人民医院

出处《实用中医内科杂志》 2012年第10期5-5,7,共2页 Journal of Practical Traditional Chinese Internal Medicine

关键词乙型肝炎慢性卢秉久病因病机辨证论治经验 Hepatitis B Chronic LU Bing-jiu Etiology and pathogenesis Syndrome differentiation Experience

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献2

1曾民德,茅益民,姚光弼,周霞秋,王豪,徐道振,姚集鲁,侯金林,王宇明,任红,陈亚岗,牛俊奇,王耀宗.阿德福韦酯治疗HBeAg阳性的中国慢性乙型病毒性肝炎患者52周的多中心临床研究[J].中华传染病杂志,2005,23(6):387-394. 被引量：164
2殷晓玲.中医辨证施治乙型肝炎方法新探[J].时珍国医国药,2006,17(5):869-870. 被引量：8

二级参考文献19

1Hadziyannis S,Tassopoulos N,Chang TT,et al.Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study.J Hepatol,2004,40(Suppl 1):17 (Abstract 46).
2Hadziyannis SJ,Papatheodoridis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Expert Rev Anti Infect Ther,2004,2:475-483.
3Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
4Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
5Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
6Delmas J,Schorr O,Jamard C,et al.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Antimicrob Agents Chemother,2002,46:425-433.
7Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
8Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.Heptology,2004,39:857-861.
9Qi X,Snow A,Thibault V,et al.Long-term incidence of Adefovir Dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Hepatol,2004,40(Suppl 1):20 (Abstract 57).
10Westland CE,Yang H,Delaney WE 4th,et al.Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Hepatology,2003,38:96-103.